Blog

Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Open filters
Search
Tags
Author
Alison Sathe
Anders Vinther
Barbara W. Unger
Jackie Torfin
Jerry Chapman
Jon Falker
Katie Terry
Mark Agostino
Rebecca Stauffer
Redica Systems
Roger Angarita
Sarah Boynton
Scott Sherrill
Subscribe to our Newsletter
Regular posts covering guidance changes, inspection findings, data methodology, and Redica product updates.

Repeat Deficiencies in Lupin Limited Warning Letters

No items found.
Conference Spotlight

FDA Expanding its Sterile Drug NIPP Inspection Pilot to Include Other Dosage Forms

No items found.
Conference Spotlight

Part 2: How Amgen Uses AI Tools To Improve Manufacturing Deviation Investigations

No items found.

Introducing Jonathan Rochez, Redica Systems’s New VP of Engineering

No items found.
Enforcement

CTP Issues First-of-a-Kind Warning Letter to JUUL Labs

No items found.
Conference Spotlight

Part 1: How Amgen Uses AI Tools To Improve Manufacturing Deviation Investigations

No items found.
Trends

Identification of Software Validation Shortcomings

No items found.

Gaining GMP Expertise: Govzilla Adds Jane Wastl as Senior GMP Quality Expert

No items found.
Trends

Recent Statement Regarding ARB Recalls

No items found.

AveXis’s New Gene Therapy Approved but New Questions Are Raised

No items found.
Enforcement

Review of the Office of Generic Drugs’ 2018 Annual Report

No items found.

MHRA’s “Right Environment”

No items found.
Trends

Analysis of CDER Report on Pharmaceutical Quality

No items found.

How Mindful Leadership Supports Data Integrity

No items found.
Trends

How Small Pharma Firms Can Prepare for a GMP Inspection in 2019

No items found.

Data Integrity Trends in 483s and Warning Letters: Part 3

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 2

No items found.
Trends

Data Integrity Trends in 483s and Warning Letters: Part 1

No items found.